28 related articles for article (PubMed ID: 28314302)
1. Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer.
Hammarström K; Nunes L; Mathot L; Mezheyeuski A; Lundin E; Korsavidou Hult N; Imam I; Osterlund E; Sjöblom T; Glimelius B
Int J Cancer; 2024 Jul; 155(1):40-53. PubMed ID: 38376070
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix.
Kim JK; Marco MR; Choi SH; Qu X; Chen CT; Elkabets M; Fairchild L; Chow O; Barriga FM; Dow LE; O'Rourke K; Szeglin B; Yarilin D; Fujisawa S; Manova-Todorova K; Paty PB; Shia J; Leslie C; Smith JJ; Lowe S; Pelossof R; Sanchez-Vega F; Garcia-Aguilar J
Mol Oncol; 2021 Oct; 15(10):2766-2781. PubMed ID: 33817986
[TBL] [Abstract][Full Text] [Related]
3. CEACAM-7: a predictive marker for rectal cancer recurrence.
Messick CA; Sanchez J; Dejulius KL; Hammel J; Ishwaran H; Kalady MF
Surgery; 2010 May; 147(5):713-9. PubMed ID: 20004437
[TBL] [Abstract][Full Text] [Related]
4. KRAS status predicted by pretreatment MRI radiomics was associated with lung metastasis in locally advanced rectal cancer patients.
Xiang Y; Li S; Song M; Wang H; Hu K; Wang F; Wang Z; Niu Z; Liu J; Cai Y; Li Y; Zhu X; Geng J; Zhang Y; Teng H; Wang W
BMC Med Imaging; 2023 Dec; 23(1):210. PubMed ID: 38087207
[TBL] [Abstract][Full Text] [Related]
5. Analysis of KRAS, NRAS, and BRAF Mutations, Microsatellite Instability, and Relevant Prognosis Effects in Patients With Early Colorectal Cancer: A Cohort Study in East Asia.
Li Y; Xiao J; Zhang T; Zheng Y; Jin H
Front Oncol; 2022; 12():897548. PubMed ID: 35837115
[TBL] [Abstract][Full Text] [Related]
6. The Advance and Correlation of
Yu K; Wang Y
Pathol Oncol Res; 2021; 27():1609906. PubMed ID: 34975345
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy.
Pectasides E; Chatzidakis I; Kotoula V; Koliou GA; Papadopoulou K; Giannoulatou E; Giannouzakos VG; Bobos M; Papavasileiou C; Chrisafi S; Florou A; Pectasides D; Fountzilas G
Cancer Genomics Proteomics; 2020; 17(3):277-290. PubMed ID: 32345669
[TBL] [Abstract][Full Text] [Related]
8. O6-methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Rectal Adenocarcinoma After Chemoradiotherapy Treatment: Clinical Implications.
Oliver JA; Gómez-Millán J; Medina JA; Cabeza L; Perazzoli G; Jimenez-Luna C; Doello K; Ortiz R
Balkan Med J; 2019 Aug; 36(5):283-286. PubMed ID: 31199091
[TBL] [Abstract][Full Text] [Related]
9. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
11. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
Clancy C; Burke JP; Coffey JC
Surg Oncol; 2013 Jun; 22(2):105-11. PubMed ID: 23473635
[TBL] [Abstract][Full Text] [Related]
12. Synovial metastasis of the knee in a
Tapia Rico G; Klevansky M; Townsend A; Price T
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28784880
[TBL] [Abstract][Full Text] [Related]
13.
Sideris M; Moorhead J; Diaz-Cano S; Haji A; Papagrigoriadis S
Anticancer Res; 2017 Mar; 37(3):1349-1357. PubMed ID: 28314302
[TBL] [Abstract][Full Text] [Related]
14. KRAS Mutant Status, p16 and β-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer.
Sideris M; Moorhead J; Diaz-Cano S; Bjarnason I; Haji A; Papagrigoriadis S
Anticancer Res; 2016 Oct; 36(10):5315-5324. PubMed ID: 27798894
[TBL] [Abstract][Full Text] [Related]
15. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
